Abstract
Skp2 is frequently overexpressed in many human cancers and plays a key role in tumorigenesis. As a component of the SCFSkp2 ubiquitin E3 ligase complex, Skp2 is responsible for recruiting substrate proteins for their ubiquitination and subsequent degradation by the 26S proteasome. Thus, Skp2 promotes the cell cycle by down-regulating cell cycle proteins such as the tumor suppressor p27. Alternatively, Skp2 suppresses p53-dependent apoptosis by outcompeting p53 for binding to p300, thereby perturbing p300-mediated p53 acetylation and stabilization. Taken together, inhibition of Skp2 functions (either proteolytic function or non-proteolytic function) is emerging as a promising and novel anti-cancer strategy. In the present review, we highlight the development of Skp2 inhibitors with different mechanisms of action.
Keywords: 26S proteasome, E3 ligase complex, Skp2 inhibitors, Skp2/p27 interaction, Tumorigenesis, Ubiquitinproteasome system.
Current Medicinal Chemistry
Title:Skp2 Inhibitors: Novel Anticancer Strategies
Volume: 23 Issue: 22
Author(s): Yeongju Lee and Hyun-Suk Lim
Affiliation:
Keywords: 26S proteasome, E3 ligase complex, Skp2 inhibitors, Skp2/p27 interaction, Tumorigenesis, Ubiquitinproteasome system.
Abstract: Skp2 is frequently overexpressed in many human cancers and plays a key role in tumorigenesis. As a component of the SCFSkp2 ubiquitin E3 ligase complex, Skp2 is responsible for recruiting substrate proteins for their ubiquitination and subsequent degradation by the 26S proteasome. Thus, Skp2 promotes the cell cycle by down-regulating cell cycle proteins such as the tumor suppressor p27. Alternatively, Skp2 suppresses p53-dependent apoptosis by outcompeting p53 for binding to p300, thereby perturbing p300-mediated p53 acetylation and stabilization. Taken together, inhibition of Skp2 functions (either proteolytic function or non-proteolytic function) is emerging as a promising and novel anti-cancer strategy. In the present review, we highlight the development of Skp2 inhibitors with different mechanisms of action.
Export Options
About this article
Cite this article as:
Lee Yeongju and Lim Hyun-Suk, Skp2 Inhibitors: Novel Anticancer Strategies, Current Medicinal Chemistry 2016; 23 (22) . https://dx.doi.org/10.2174/0929867323666160510122624
DOI https://dx.doi.org/10.2174/0929867323666160510122624 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exogenous Expression of WNT7A in Leukemia-Derived Cell Lines Induces Resistance to Chemotherapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Muscular Dystrophies: Histology, Immunohistochemistry, Molecular Genetics and Management
Current Pharmaceutical Design Circulating Tumor Stem Cells as Biomarkers for Cancer Progression
Recent Patents on Biomarkers Targeted Drug Delivery Via Human Epidermal Growth Factor Receptor for Sustained Release of Allyl Isothiocyanate
Current Topics in Medicinal Chemistry Castration Resistant Prostate Cancer: From Emerging Molecular Pathways to Targeted Therapeutic Approaches
Clinical Cancer Drugs Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma
Current Radiopharmaceuticals Small-Molecule Inhibitors Targeting eIF4A in Leukemia
Current Protein & Peptide Science Regulation of P2X3 Receptor Structure and Function
CNS & Neurological Disorders - Drug Targets The Human Desmin Promoter Drives Robust Gene Expression for Skeletal Muscle Stem Cell-Mediated Gene Therapy
Current Gene Therapy A Functional Scaffold in Marine Alkaloid: An Anticancer Moiety for Human
Current Medicinal Chemistry Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design Sentinel Node in Endometrial Cancer: Rationale and Early Experience
Current Women`s Health Reviews Identification and Induction of Cytochrome P450s Involved in the Metabolism of Flavone-8-Acetic Acid in Mice
Drug Metabolism Letters Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Current Signal Transduction Therapy microRNAs-based Predictor Factor in Patients with Migraine-ischemic Stroke
MicroRNA Multi-Nuclear Platinum Drugs: A New Paradigm in Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Characterization of β-Sitosterol for Potential Selective GR Modulation
Protein & Peptide Letters